And really, due to continuous disclosure obligations, if RCE had data from their latest trial that R327 was effective in sepsis, they would be obligated to report it.
A more cynical person might even suggest that the reason they rebranded their fast IV trial to be a "UTI" trial is precisely so they WOULDN'T have to report any adverse plasma/sepsis results....
RCE Price at posting:
42.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)